SHORT MINI FUTURE - GILEAD SCIENCES | Market Closed - Swiss Exchange 16:20:00 30/05/2024 BST | ||
| 1.53 CHF | -1.29% |
|
| Current month | +4.79% | ||
| 1 month | +4.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 30/05/24 | 1.53 | -1.29% |
| 29/05/24 | 1.55 | +4.73% |
| 28/05/24 | 1.48 | +2.07% |
| 27/05/24 | 1.45 | +0.69% |
| 24/05/24 | 1.44 | +4.35% |
Delayed Quote Swiss Exchange
Last update May 30, 2024 at 04:20 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Bank Julius Bär |
| LGIDJB | |
| ISIN | CH1219346017 |
| Date issued | 11/11/2022 |
| Strike | 96.68 $ |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.55 CHF |
|---|---|
| Lowest since issue | 0.46 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.65% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.27
USD
Average target price
82.7
USD
Spread / Average Target
+28.67%
- Stock Market
- Certificates
- LGIDJB Certificat
